Citius Pharmaceuticals Inc. (CTXR) shares surged 22.12% in after-hours trading to $1.27 on Tuesday, and the reason is pretty straightforward: the company finally launched its first commercial product after years of development work.

A New Treatment Option After Six Years

The New Jersey-based biopharmaceutical company announced that LYMPHIR (denileukin diftitox-cxdl), a recombinant engineered fusion protein, became commercially available in December through its subsidiary Citius Oncology (CTOR). This is the first new FDA-approved therapy for cutaneous T-cell lymphoma (CTCL) since 2018, which matters quite a bit if you're a patient who's run out of options.

The therapy is approved for adult patients with relapsed or refractory Stage I-III CTCL who have already tried at least one prior systemic therapy. In other words, it's for people whose cancer came back or didn't respond to earlier treatments.

Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, said in the company's press release, "This milestone reflects our ability to execute and our commitment to delivering impactful treatments for patients with limited options."

The Infrastructure Behind the Launch

Getting FDA approval is one thing. Actually getting your drug to patients who need it is another challenge entirely, and Citius seems to have checked the necessary boxes. The company secured a permanent Healthcare Common Procedure Coding System J-code (J9161), which is critical for insurance reimbursement, along with a National Comprehensive Cancer Network Category 2A recommendation.

According to the company, service agreements with three leading U.S. pharmaceutical wholesalers provide nationwide distribution capability, with an estimated 18 months of commercial supply already secured. The therapy is also available in 19 international markets through named patient programs.

Management estimates LYMPHIR's initial addressable market exceeds $400 million, which would be transformative for a company currently valued at less than $17 million.

The Financial Reality Check

Here's where things get interesting. Citius reported a fiscal 2025 net loss of $39.7 million, or $3.38 per share, compared with a net loss of $40.2 million, or $5.97 per share, in fiscal 2024. The company raised roughly $61 million in gross proceeds through capital raises during the year but had just $4.3 million in cash and cash equivalents as of September 30.

Research and development expenses fell to $9.2 million from $11.9 million year over year, while general and administrative expenses rose slightly to $18.5 million from $18.2 million. The company reported no revenue for fiscal 2025, which makes sense given LYMPHIR only launched in December.

What the Charts Say

Citius Pharmaceuticals has a Relative Strength Index (RSI) of 42.25 and a market capitalization of $16.57 million. The stock has a 52-week high of $5.95 and a 52-week low of $0.65.

Over the past 12 months, CTXR has declined 66.77%, reflecting the struggles typical of pre-revenue biotech companies. This long-term downtrend shows just how challenging the path has been.

Price Action: Citius Pharmaceuticals closed on Tuesday at $1.04, down 0.95%. The stock is currently about 7.4% above its 52-week low, positioning it much closer to its lows than its highs. The after-hours surge suggests investors see the commercial launch as potentially game-changing, though the company's cash position means further financing will likely be needed.